{
    "2018-12-19": [
        [
            {
                "time": "",
                "original_text": "富士莱医药IPO失利: 年内被否第59家  毛利率高于同行  IPO融资异常",
                "features": {
                    "keywords": [
                        "富士莱医药",
                        "IPO",
                        "毛利率",
                        "融资异常"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019",
                "original_text": "2019年证券行业投资策略: 证券板块估值修复, 行业方兴未艾",
                "features": {
                    "keywords": [
                        "证券行业",
                        "投资策略",
                        "估值修复",
                        "方兴未艾"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "证券"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}